Nordic guidelines on the diagnosis and treatment of
patients with Myeloproliferative Neoplasms
The Nordic study group on myeloproliferative neoplasms (NMPN) is a pan-Nordic
organization that has conducted Nordic clinical trials since 2001. NMPN decided in 2006 to
write new guidelines, based on already existing national guidelines from the Nordic countries,
Italy1 and Great Britain.2 The first version was published in 2007. The aim has been to write a
document that can be used in all Nordic countries.
We have strived to use evidence-based medicine, i.e. the conscientious, explicit,
and judicious use of current best evidence in making decisions on our recommendations.
The grading system employed in these guidelines is detailed on page 31.
However, it should be stressed that few randomized controlled trials exist
in the MPNs to support decision-making for individual patients.
The guidelines are written for health professionals with a specialty or interest in hematology. They have now been updated in 2013, and are for the most part similar to those recently published by the European Leukemia Net.3 This is the third update since our guidelines were first published.
